Pitches · 8:00–9:30 AM PT
Resuture
Hannah Eherenfeldt, CEO · hannah@resuture.com
ReSuture creates synthetic veins, arteries, and human tissues for surgical and medical device training.
Round
1250000 Convertible Note @ $5M cap
Closed
1000000
FDA milestone
N/A
FDA timeline
N/A
Other groups in round
Golden Seeds, Pasadena Angels
DD package
yes
Traction: ~$500M in revenue 2025
What they're looking for: Customer introductions
Haystack
Aykut Aksit, CEO · aykut@haystackmedical.com
Microscale needles for precise inner-ear drug delivery and diagnostics.
Round
$2M Convertible Note @ $12M pre-money
Closed
$145K raised ($45K received, $100K committed)
FDA milestone
Preclinical; bench testing complete, regulatory pathway defined; preparing for first-in-human feasibility study.
FDA timeline
FDA submission expected within 4-6 months, approval within 12-16 months.
Other groups in round
NY Ventures, Access Industries
DD package
Yes
Traction: LOI from Sensorion; in conversation with 3+ parties about paid pilots; defined university hospital partner for first-in-human study.
What they're looking for: Regulatory advisors with early-stage device experience